What You Should Know:
– Today Innovaccer, the Health Cloud company, announced its Connected Digital Health solution, a new way for life sciences companies to rapidly deliver next-generation digital apps that surround therapeutics and devices with highly engaging patient experiences, improve clinical outcomes, and generate valuable real-world evidence (RWE).
– The new solution will allow life sciences companies to realize the promise of digital health with holistic, “around-the-brand” experiences that connect brands, providers, and patients.
Speed Time-to-Market of Patient-Centric Apps
“Creating digital health apps with a unified brand-provider-patient workflow is the next great vista for pharma brands and we can help them cross it,” said Kanav Hasija, chief customer officer and cofounder of Innovaccer. “In an increasingly crowded market, launching another ‘me-too’ app isn’t enough for brands to succeed. Pharma brands must surround their products with ‘sticky’ experiences that exceed patients’ expectations when compared to the disconnected, point-solution apps patients typically ignore. With Innovaccer, pharma will be able to put an end to health app abandonment with connected health applications that patients really want to use.”
With Innovaccer’s Connected Digital Health solution, biopharma and medtech companies will be able to speed time-to-market of patient-centric apps that connect patients to their care teams and deliver real-time health insights into their physicians’ workflows. Providers and patients alike will be able to act on these insights to improve care management and adherence, factors proven to enhance the quality of care.
In addition, Innovaccer’s Connected Digital Health solution will enable patient- and population-level RWE to be generated and delivered to biopharma and medtech brands for indicating their real-world use, benefits, and potential target populations; identifying label expansion opportunities, supporting clinical trial designs and observational studies—ultimately providing crucial insights for further drug and device innovation.
